Shanghai Fosun Pharmaceutical Group Co Ltd has agreed to buy an 86 percent stake in Gland Pharma: for up to $1.3 billion, the largest acquisition of an Indian company from abroad yet this year.
The deal was announced by both sides on July 28, and is the first major move by the Fosun group since Guo Guangchang, founder of flagship holding firm Fosun International Ltd and one of China’s best-known entrepreneurs, went missing for a short period of time late last year.
The acquisition, if it passes regulatory approvals, would also underscore a positive outlook for drugmakers in India, which are a major global supplier and count the United States as their largest export market, helped by lower manufacturing and labor costs.
Fosun stated it would buy 86.1 percent of Gland, and planned to raise a maximum of $800 million in loans from financial institutions to help fund the deal.
Full Content: Channel News Asia
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Spanish Startup Association Slams Microsoft’s Cloud Practices
May 7, 2024 by
CPI
TikTok and ByteDance File Lawsuit Against US Law Mandating App Sale
May 7, 2024 by
CPI
Apollo, Sony Bid to Acquire Paramount Faces Regulatory Hurdles
May 7, 2024 by
CPI
Turkey Fines Meta $10.4 Million for Abusing Market Dominance
May 6, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI